Technology

DuChemBio Co, LTD Reports 33% Increase in Sales of Dementia Diagnostic Test… Third-Quarter Revenue Reaches 11 Billion Won

NeuraCheck and Vizamil Report Cumulative Sales of 7.1 Billion Won… Quarterly Growth Supply Chain Expansion Ahead of Kisunra Launch… Plans Underway for New Plant in Jeongeup

NA EUN-KYUNG
2026-11-17 19:54:02
[Edaily Reporter NA EUN-KYUNG ] DuChemBio Co.,LTD.(176750)continued its revenue growth in the third quarter, driven by increased sales of radiopharmaceuticals for the diagnosis of Alzheimer’s disease. With the domestic launch of Eli Lilly’s “Kisunra” imminent, following the existing treatment “Lecembi,” demand for related diagnostic products is expected to expand further.

DuChemBio Co, LTD announced on the 16th that its third-quarter revenue reached 11 billion won, an 11.1% increase compared to the same period last year. Operating profit stood at 1.9 billion won, remaining at the same level as the previous year. Cumulative operating profit for the first three quarters of this year totaled 5.1 billion won, a 14.0% increase year-over-year.

The products driving this growth were the radiopharmaceuticals “NeuraCheck” and “Vizamil,” used for diagnosing Alzheimer’s disease. Combined sales of these two products for the first three quarters of this year totaled 7.1 billion won, a 32.7% increase compared to the same period last year. Quarterly sales also rose steadily, reaching 2.1 billion won in the first quarter, 2.4 billion won in the second quarter, and 2.6 billion won in the third quarter. Cumulative sales volume reached 16,959 doses, a 33.6% increase compared to the same period last year.

An amyloid PET scan is a test that uses imaging to detect beta-amyloid protein accumulation in the brain. To administer the Alzheimer’s disease treatment Lecembi, amyloid pathology must be confirmed through a PET scan or cerebrospinal fluid (CSF) test.

Kisunra, which is set to launch in Korea, can also utilize PET scans during the course of treatment. If the accumulation of amyloid in the brain decreases sufficiently, discontinuation of the medication can be considered based on the test results, leading to an expected increase in demand for diagnostic agents.

DuChemBio Co, LTD currently supplies products to approximately 120 medical institutions from five manufacturing sites nationwide. Due to the short half-life of radioisotopes, delivery time between production facilities and medical institutions is critical for radiopharmaceuticals. The company signed an investment agreement worth 34.3 billion won last September and is moving forward with the construction of a Contract Development and Manufacturing Organization (CDMO) facility for radiopharmaceuticals in Jeongeup, North Jeolla Province. The first phase of the facility is scheduled to begin operations in the second half of 2029.

Sales of other diagnostic agents also increased. Quarterly sales of “Prostasic,” a prostate cancer diagnostic agent, rose from 300 million won to 500 million won, while “FP-CIT,” a Parkinson’s disease diagnostic agent, recorded third-quarter sales of 1.2 billion won. The company has completed the Drug Master File (DMF) registration with the U.S. Food and Drug Administration (FDA) for the FP-CIT raw material and is preparing to enter the U.S. market.

Kim Sang-woo, CEO of DuChemBio Co, LTD, stated, “Even in a market with only one available treatment, the demand for diagnostics has already been confirmed by our financial results,” adding, “If the number of prescribable drugs increases to two, the demand for testing will also grow accordingly.”

Economy

Corporation

IT·Science

Economy

SamsungElectroMechanics Breaks Into Big Tech… Share of SamsungElectronics’ Revenue Declines

It has been revealed that the share of SamsungElectronics and its subsidiaries in SamsungElectroMechanics’ total revenue has decreased. As business with global big tech companies expands, particularly…
2026-11-17 17:07:26

Corporation

Selling More Yields Less Profit, Selling Less Yields More Profit… The Food Industry’s Growth Formula Is Shaken

The food industry’s third-quarter earnings this year revealed a business environment in which it has become difficult to secure profitability through sales growth alone. While some companies saw their…
2026-11-17 18:02:29

IT·Science

DuChemBio Co, LTD Reports 33% Increase in Sales of Dementia Diagnostic Test… Third-Quarter Revenue Reaches 11 Billion Won

DuChemBio Co.,LTD.(176750)continued its revenue growth in the third quarter, driven by increased sales of radiopharmaceuticals for the diagnosis of Alzheimer’s disease. With the domestic launch of Eli…
2026-11-17 19:54:02